CeleCor Therapeutics   Report issue

For profit Phase 2
Founded: San Diego CA United States (2017)

Organization Overview

First Clinical Trial
2019
NCT03844191
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CeleCor Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

Zalunfiban (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Disease (Phase 2)

Heart Diseases (Phase 2)

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1